Definitive Contract 75N93019C00060
Award Date
9/4/19
Potential Completion Date
4/24/25
Potential Value
$22M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Versatope Therapeutics Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Lowell, MA 01852, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $33,273,522 cost-plus-fixed-fee definitive contract to Anivive Lifesciences Inc., a self-certified small disadvantaged business, to develop vaccine candidates for biodefense and emerging infectious diseases. This contract, awarded on June 7, 2024, is part of NIAID's Broad Agency Announcement (BAA) research program and has a completion date of June 1, 2026. The contract...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), awarded a $13.6 million cost plus fixed fee delivery order contract to Leidos Biomedical Research, Inc. to support the Vaccine Research Center's (VRC) mission scope including research and development of vaccines and therapeutics for the prevention and treatment of diseases of human concern, including malaria, at their...
This federal contract award, valued at $16,731,358.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute. The contract is for the continued development of vaccine candidates for biodefense, antimicrobial resistance, emerging infectious diseases, and respiratory pathogens. No set-aside designation was used. AAHI has subcontracted with several institutions, including Emory...
This $18,576,013.05 federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Access To Advanced Health Institute (AAHI), a nonprofit biotech research institute located in Seattle, Washington. The contract is for the "Development of Vaccine Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections, and Emerging Infectious Diseases" under NIAID's Broad Agency Announcement (BAA) Research Area 001. This is a...
This is a cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Vaxine PTY LTD, a for-profit organization located in Australia. The $18,541,473.00 contract is for the "ADVANCED DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has an end date of August 14, 2023 and was initially awarded on September 20, 2018. This contract...
This federal contract award to Microbiotix, Inc., a clinical-stage biopharmaceutical company, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), under a Broad Agency Announcement (BAA). The $14,195,727 cost-plus-fixed-fee contract supports the development of small molecule pan-filovirus entry inhibitors through lead optimization, selection of a preclinical candidate, and IND-enabling preclinical studies. The...
The University of Massachusetts Medical School was awarded a $7.45 million cost-no-fee definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to develop and manufacture a GMP-grade Neisseria gonorrhoeae multi-peptide vaccine candidate known as TMCP2 and advance it through a Phase I clinical trial. Three subcontracts were issued in support of this effort, including to Advanced Bioscience Laboratories to perform immunogenicity testing,...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The $99,299 cost-plus-fixed-fee delivery order was placed under the Therapeutics Against Infectious Diseases Phase 1 IDIQ contract, which funds Phase I clinical trials for therapeutic products targeting infectious diseases. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General Dynamics...
This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to International AIDS Vaccine Initiative Inc. (IAVI), a non-profit organization. The $713,906.00 award supports the development of nanoparticle-based delivery systems for human immunodeficiency virus type 1 (HIV-1) biomolecules. The contract has a performance period ending on December 15, 2021 and utilizes a Cost...
The federal contract award HHSN272200800039C was a $8,394,390.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Vaxine PTY LTD, a for-profit organization, on September 30, 2008. The contract is part of NIAID's Adjuvant Discovery Program and is for biomedical research services. It has a cost-no-fee pricing type and an ultimate completion date of September 29, 2013. The contract was not set aside for any specific business...